Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0013841017
Tue, 12.11.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites 12.11.2024 / 07:00 CET/CEST
The expansion of bioconjugation capabilities will provide additional manufacturing capacity for launch and commercial supply, addressing growing market demand
2,000m2 of manu [ … ]
Tue, 22.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership/Agreement
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates 22.10.2024 / 07:00 CET/CEST
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and [ … ]
Thu, 03.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Nominates David Meline as Independent Board Member 03.10.2024 / 09:00 CET/CEST
David Meline brings extensive governance, financial and industry experience to Lonza’s Board of Directors
Olivier Verscheure will not stand for re-election at the 2025 Annual General Meeting
Basel, Sw [ … ]
Tue, 01.10.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Acquisition
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST
The Vacaville site is one of the largest biologics manufacturing facilities in the world
Acquisition extends Lonza’s US Biologics footprint with a significant presence on [ … ]
Tue, 24.09.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Partnership
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) 24.09.2024 / 14:00 CET/CEST
Lonza to manufacture CASGEVY®, the world’s first CRISPR/Cas9 gene-edited cell therapy, for global commercial supply
CASGEVY® will be manufactured at Lonza [ … ]
Wed, 28.08.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond
Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds 28.08.2024 / 18:31 CET/CEST
Basel, Switzerland, 28 August 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of its dual tranche EUR 1.2 billion straight bonds. [ … ]
Thu, 25.07.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members 25.07.2024 / 07:00 CET/CEST
Basel, Switzerland, 25 July 2024 - Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to [ … ]
Mon, 01.07.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand 01.07.2024 / 07:00 CET/CEST
Wolfgang Wienand commences his tenure as Chief Executive Officer of Lonza Group
Albert M. Baehny will retire from Lonza Group following a transition period
Basel, Switzerland, 1 July 2024 – Wol [ … ]
Wed, 08.05.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): AGMEGM
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved 08.05.2024 / 15:00 CET/CEST
Jean-Marc Huët was elected as Chairman of the Board of Directors
Shareholders re-elected all members of the Board of Directors standing for re-elect [ … ]
Wed, 17.04.2024
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon 17.04.2024 / 19:00 CET/CEST
Basel, Switzerland, 17 April 2024 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 1 billion straight bond. The [ … ]